MX2018014443A - 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas. - Google Patents
3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas.Info
- Publication number
- MX2018014443A MX2018014443A MX2018014443A MX2018014443A MX2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- dihydropyridazine
- diphenyl
- oxo
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención cubre compuestos de 3-oxo-2,6-difenil-2,3-di hidropiridazin-4-carboxamida de fórmula general (I): (ver Fórmula) en la cual R1, R2, R3, R4, R5 y R6 son según lo definido en la presente invención, métodos para preparar dichos compuestos, compuestos intermedios útiles para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y la utilización de dichos compuestos para manufacturar composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular del cáncer o afecciones con respuestas inmunes desreguladas u otros trastornos asociados con la señalización aberrante del AHR, como un agente único o en combinación con otros ingredientes activos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016083308 | 2016-05-25 | ||
CN2017074408 | 2017-02-22 | ||
PCT/EP2017/062355 WO2017202816A1 (en) | 2016-05-25 | 2017-05-23 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018014443A true MX2018014443A (es) | 2019-04-15 |
Family
ID=58745251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018014443A MX2018014443A (es) | 2016-05-25 | 2017-05-23 | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas. |
Country Status (27)
Country | Link |
---|---|
US (1) | US11040035B2 (es) |
EP (1) | EP3464248B1 (es) |
JP (1) | JP6964096B2 (es) |
KR (1) | KR20190009369A (es) |
CN (1) | CN109863140B (es) |
AU (1) | AU2017269870A1 (es) |
BR (1) | BR112018074185A2 (es) |
CA (1) | CA3025227A1 (es) |
CL (1) | CL2018003345A1 (es) |
CO (1) | CO2018012654A2 (es) |
CR (1) | CR20180556A (es) |
CU (1) | CU20180143A7 (es) |
DO (1) | DOP2018000256A (es) |
EA (1) | EA201892666A1 (es) |
EC (1) | ECSP18087725A (es) |
IL (1) | IL263046A (es) |
MA (1) | MA45087A (es) |
MX (1) | MX2018014443A (es) |
NI (1) | NI201800124A (es) |
PE (1) | PE20190509A1 (es) |
PH (1) | PH12018502472A1 (es) |
SG (1) | SG11201810366WA (es) |
SV (1) | SV2018005787A (es) |
TN (1) | TN2018000392A1 (es) |
TW (1) | TW201742859A (es) |
UY (1) | UY37256A (es) |
WO (1) | WO2017202816A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI759301B (zh) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
JOP20190193A1 (ar) * | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان |
US11591311B2 (en) | 2017-11-21 | 2023-02-28 | Bayer Aktiengesellschaft | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
EA037978B1 (ru) * | 2017-11-21 | 2021-06-18 | Байер Акциенгезельшафт | 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования |
WO2019101647A1 (en) * | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors |
CA3082856A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
BR112021003529A2 (pt) | 2018-08-24 | 2021-05-18 | Jaguahr Therapeutics Pte Ltd | derivados de tetra-hidropiridopirimidina como moduladores de ahr |
EP3843853A1 (en) | 2018-08-31 | 2021-07-07 | Jaguahr Therapeutics Pte Ltd | Heterocyclic compounds as ahr modulators |
CN109771437B (zh) * | 2019-03-28 | 2023-03-17 | 西安交通大学医学院第一附属医院 | 三氟胸苷在制备治疗三阴性乳腺癌药物中的应用 |
EP3715471A1 (en) | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
EP3721894A1 (en) | 2019-04-10 | 2020-10-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof |
JPWO2021020362A1 (es) * | 2019-07-29 | 2021-02-04 | ||
EP3835432A1 (en) | 2019-12-10 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer |
EP4076462A1 (en) * | 2019-12-16 | 2022-10-26 | Bayer Aktiengesellschaft | Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer |
KR20220125323A (ko) | 2020-01-10 | 2022-09-14 | 이케나 온콜로지, 인코포레이티드 | Ahr 억제제 및 이의 용도 |
AU2021226411A1 (en) | 2020-02-26 | 2022-09-22 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of AhR signalling |
US20230150970A1 (en) * | 2020-03-27 | 2023-05-18 | Dong-A St Co., Ltd. | Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators |
US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
WO2022078356A1 (zh) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
CN114685426A (zh) * | 2020-12-28 | 2022-07-01 | 苏州泽璟生物制药股份有限公司 | 磺酰胺类抑制剂及其制备方法和应用 |
TW202320777A (zh) * | 2021-09-14 | 2023-06-01 | 中國大陸商元啟(蘇州)生物製藥股份有限公司 | 芳基烴受體調節劑及其用於治療疾病及病症之用途 |
WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
KR100657189B1 (ko) * | 1998-08-14 | 2006-12-14 | 니혼노야쿠가부시키가이샤 | 피리다지논 유도체 및 이를 함유하는 의약 조성물 |
CN100473647C (zh) | 2000-09-18 | 2009-04-01 | 卫材R&D管理有限公司 | 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途 |
FR2847253B1 (fr) | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
FR2847235B1 (fr) | 2002-11-20 | 2005-07-08 | Essilor Int | Emballage de protection et de calage pour objets a contour circulaire |
WO2007058392A1 (ja) | 2005-11-21 | 2007-05-24 | Japan Tobacco Inc. | ヘテロ環化合物およびその医薬用途 |
WO2009142732A2 (en) | 2008-05-20 | 2009-11-26 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
EP2598138B1 (en) | 2010-07-27 | 2020-05-06 | Trustees of Boston University | Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
US20170173008A1 (en) | 2014-03-19 | 2017-06-22 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
-
2017
- 2017-05-23 WO PCT/EP2017/062355 patent/WO2017202816A1/en unknown
- 2017-05-23 MX MX2018014443A patent/MX2018014443A/es unknown
- 2017-05-23 US US16/303,539 patent/US11040035B2/en active Active
- 2017-05-23 CU CU2018000143A patent/CU20180143A7/es unknown
- 2017-05-23 JP JP2018561224A patent/JP6964096B2/ja active Active
- 2017-05-23 EP EP17724833.3A patent/EP3464248B1/en active Active
- 2017-05-23 KR KR1020187037050A patent/KR20190009369A/ko not_active Application Discontinuation
- 2017-05-23 CA CA3025227A patent/CA3025227A1/en active Pending
- 2017-05-23 SG SG11201810366WA patent/SG11201810366WA/en unknown
- 2017-05-23 CR CR20180556A patent/CR20180556A/es unknown
- 2017-05-23 MA MA045087A patent/MA45087A/fr unknown
- 2017-05-23 PE PE2018003109A patent/PE20190509A1/es unknown
- 2017-05-23 EA EA201892666A patent/EA201892666A1/ru unknown
- 2017-05-23 TN TNP/2018/000392A patent/TN2018000392A1/en unknown
- 2017-05-23 CN CN201780046149.5A patent/CN109863140B/zh active Active
- 2017-05-23 AU AU2017269870A patent/AU2017269870A1/en not_active Abandoned
- 2017-05-23 BR BR112018074185-0A patent/BR112018074185A2/pt not_active IP Right Cessation
- 2017-05-24 UY UY0001037256A patent/UY37256A/es not_active Application Discontinuation
- 2017-05-25 TW TW106117299A patent/TW201742859A/zh unknown
-
2018
- 2018-11-15 IL IL263046A patent/IL263046A/en unknown
- 2018-11-23 DO DO2018000256A patent/DOP2018000256A/es unknown
- 2018-11-23 NI NI201800124A patent/NI201800124A/es unknown
- 2018-11-23 CO CONC2018/0012654A patent/CO2018012654A2/es unknown
- 2018-11-23 PH PH12018502472A patent/PH12018502472A1/en unknown
- 2018-11-23 EC ECSENADI201887725A patent/ECSP18087725A/es unknown
- 2018-11-23 CL CL2018003345A patent/CL2018003345A1/es unknown
- 2018-11-23 SV SV2018005787A patent/SV2018005787A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP18087725A (es) | 2018-11-30 |
DOP2018000256A (es) | 2019-02-15 |
EP3464248B1 (en) | 2021-09-08 |
EP3464248A1 (en) | 2019-04-10 |
NI201800124A (es) | 2019-04-29 |
CA3025227A1 (en) | 2017-11-30 |
TN2018000392A1 (en) | 2020-06-15 |
CL2018003345A1 (es) | 2019-03-15 |
IL263046A (en) | 2018-12-31 |
US11040035B2 (en) | 2021-06-22 |
CO2018012654A2 (es) | 2018-12-14 |
SG11201810366WA (en) | 2018-12-28 |
EA201892666A1 (ru) | 2019-08-30 |
PE20190509A1 (es) | 2019-04-10 |
CU20180143A7 (es) | 2019-07-04 |
AU2017269870A1 (en) | 2018-12-06 |
JP2019516744A (ja) | 2019-06-20 |
MA45087A (fr) | 2021-05-26 |
WO2017202816A1 (en) | 2017-11-30 |
CN109863140B (zh) | 2023-02-21 |
UY37256A (es) | 2018-01-02 |
CR20180556A (es) | 2019-04-23 |
SV2018005787A (es) | 2019-02-07 |
BR112018074185A2 (pt) | 2019-03-06 |
US20200237757A1 (en) | 2020-07-30 |
JP6964096B2 (ja) | 2021-11-10 |
CN109863140A (zh) | 2019-06-07 |
KR20190009369A (ko) | 2019-01-28 |
PH12018502472A1 (en) | 2019-09-23 |
TW201742859A (zh) | 2017-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502472A1 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
PH12019501846A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
PH12019501034A1 (en) | New anthelmintic quinoline-3-carboxamide derivatives | |
PH12018550173A1 (en) | Pyrazolopyrimidine derivatives | |
PH12020500257A1 (en) | Quinoline derivatives for treating infections with helminths | |
PH12019502851A1 (en) | New azaquinoline derivatives | |
WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
MX2022006466A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune. | |
PH12020551891A1 (en) | New quinoline derivatives | |
MX2019012803A (es) | Nuevos derivados de pirazol biciclicos. | |
WO2017198341A8 (en) | MACROCYCLIC INDOLE DERIVATIVES | |
MX2022001803A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas. | |
MX2020001404A (es) | Dihidrooxadiazinonas. | |
PH12020550494A1 (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors | |
MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
EA201991835A1 (ru) | 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования |